<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524186</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000562762</org_study_id>
    <secondary_id>RPCI-I-69605</secondary_id>
    <nct_id>NCT00524186</nct_id>
  </id_info>
  <brief_title>Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer</brief_title>
  <official_title>Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
      such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth
      of tumor cells, either by killing the cells or by stopping them from dividing. Giving
      sunitinib together with combination chemotherapy may kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of sunitinib when
      given together with irinotecan, fluorouracil, and leucovorin in treating patients with
      advanced stomach cancer or gastroesophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the maximum tolerated dose of sunitinib malate when administered with FOLFIRI
           chemotherapy comprising irinotecan hydrochloride, fluorouracil, and leucovorin calcium
           in patients with advanced gastroesophageal cancer.

      Secondary

        -  Determine the response rates, overall survival, and progression-free survival of
           patients treated with this regimen.

        -  Determine if there is a change in circulating endothelial precursor cell number and VEGF
           expression as a result of this therapy and if these changes correlate with improved
           response and survival.

        -  Document any pharmacokinetic interactions between irinotecan hydrochloride and sunitinib
           malate.

        -  Study pharmacokinetics of sunitinib malate on day 14 (steady state) and day 42 (after 6
           weeks of continuous dosing).

      OUTLINE: Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in
      course 1 and on days 1-28 in all subsequent courses. Patients also receive FOLFIRI
      chemotherapy comprising irinotecan hydrochloride IV over 90 minutes, fluorouracil IV
      continuously over 46 hours, and leucovorin calcium IV over 2 hours beginning on days 1 and
      15. Treatment repeats every 4 weeks for up to 12 months in the absence of disease progression
      or unacceptable toxicity.

      Blood is collected at baseline and periodically during study for pharmacokinetic and
      biomarker correlative studies. Samples are analyzed by flow cytometry to assess circulating
      endothelial cells and VEGF expression.

      After completion of study treatment, patients are followed for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left institute
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of sunitinib malate when administered with FOLFIRI chemotherapy (i.e., irinotecan hydrochloride, fluorouracil, and leucovorin calcium)</measure>
    <time_frame>30 days after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate as assessed by RECIST criteria</measure>
    <time_frame>Every 3 months up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Every 3 months up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating endothelial precursor cell (CEC) number</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF expression</measure>
    <time_frame>At Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of pre- and post-therapy changes in CEC number and VEGF expression with response rate and survival</measure>
    <time_frame>Every 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Oral Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sunitinib malate on day -7 and then once daily on days 2-28 in course 1 and on days 1-28 in all subsequent courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>Taken Orally</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative Study</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative Study</description>
    <arm_group_label>Oral Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

        Inclusion criteria:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Locally advanced or unresectable gastric cancer

               -  Metastatic gastric adenocarcinoma

               -  Metastatic gastroesophageal junction (GEJ) adenocarcinoma

                    -  Esophageal adenocarcinomas with involvement of GEJ allowed

        Exclusion criteria:

          -  Symptomatic, uncontrolled CNS metastases

        PATIENT CHARACTERISTICS:

        Inclusion criteria:

          -  ECOG performance status 0-1

          -  Life expectancy &gt; 12 weeks

          -  WBC ≥ 3,000/μL

          -  Platelet count ≥ 100,000/μL

          -  Creatinine ≤ 1.5 mg/dL

          -  Bilirubin ≤ 1.5 mg/dL

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        Exclusion criteria:

          -  Uncontrolled infection

          -  Uncontrolled serious medical disease

          -  Uncontrolled hypertension

          -  Coagulopathy or bleeding disorder

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to sunitinib malate or other agents used in study

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  No prior chemotherapy for metastatic disease

          -  Concurrent therapeutic anticoagulation allowed

        Exclusion criteria:

          -  Other concurrent investigational therapy

          -  Concurrent combination antiretroviral therapy in HIV-positive patients

          -  Major surgery or radiotherapy within the past 3 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Boland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

